Brázda E, Makó J, Jansen J
Semmelweis Orvostudományi Egyetem, Urológiai Klinika.
Orv Hetil. 1995 Dec 10;136(50):2715-20.
Between 1978 and 1992, 534 patients--including 35 (25 IDDM and 10 NIDDM) diabetics--were accepted to chronic hemodialysis (HD) at our Dialysis Center. The 1-year cumulative survival rate (CSR) was significantly lower in diabetic vs. non-diabetic group (66 +/- 8% vs. 78 +/- 2%), p < 0.05). At the onset of diabetes the mean age of IDDM patients vs. NIDDM patients was 18.2 +/- 2.7 years vs. 51.3 +/- 3.1 years, respectively. At the beginning of HD treatment the mean age of IDDM patients vs. NIDDM patients was 38 +/- 2.4 years vs. 58.3 +/- 2.6 years. In IDDM group until the start of HD treatment the mean duration of diabetes was 20 +/- 1.3 years and it did not depend on the quality of preuraemic metabolic control (p = 0.825); mean duration of diabetes until their death was 22.5 +/- 1.3 years. Mean age of IDDM and NIDDM patients at their death was 38.8 +/- 3 years and 60.5 +/- 3.7 years. Average duration of HD treatment was 16 +/- 2.5 months in IDDM group and 21.5 +/- 5.8 months in NIDDM group. Major causes of death were cardiovascular complications of diabetes (39%) and infections (33%). We found no difference in CSR related to gender, age, type of diabetes, quality of metabolic control during the HD treatment, but CSR was significantly higher in patients with good metabolic control from the onset of diabetes (1-year CSR of adequately vs. poorly controlled diabetics: 80% vs. 62%, p < 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)
1978年至1992年间,534例患者——包括35例(25例胰岛素依赖型糖尿病和10例非胰岛素依赖型糖尿病)糖尿病患者——在我们的透析中心接受了慢性血液透析(HD)治疗。糖尿病组与非糖尿病组的1年累积生存率(CSR)显著较低(分别为66±8%和78±2%),p<0.05。糖尿病发病时,胰岛素依赖型糖尿病患者与非胰岛素依赖型糖尿病患者的平均年龄分别为18.2±2.7岁和51.3±3.1岁。在血液透析治疗开始时,胰岛素依赖型糖尿病患者与非胰岛素依赖型糖尿病患者的平均年龄分别为38±2.4岁和58.3±2.6岁。在胰岛素依赖型糖尿病组中,直到血液透析治疗开始时,糖尿病的平均病程为20±1.3年,且不依赖于尿毒症前期代谢控制的质量(p = 0.825);直到死亡时糖尿病的平均病程为22.5±1.3年。胰岛素依赖型糖尿病和非胰岛素依赖型糖尿病患者死亡时的平均年龄分别为38.8±3岁和60.5±3.7岁。胰岛素依赖型糖尿病组血液透析治疗的平均时长为16±2.5个月,非胰岛素依赖型糖尿病组为21.5±5.8个月。主要死亡原因是糖尿病的心血管并发症(39%)和感染(33%)。我们发现,与性别、年龄、糖尿病类型、血液透析治疗期间的代谢控制质量无关的累积生存率无差异,但从糖尿病发病起代谢控制良好的患者累积生存率显著更高(血糖控制良好与控制不佳的糖尿病患者1年累积生存率:80%对62%,p<0.05)。(摘要截选至250字)